{
    "clinical_study": {
        "@rank": "75513", 
        "arm_group": {
            "arm_group_label": "bevacizumab", 
            "description": "Patients with metastatic colorectal cancer who accept treatment with chemotherapy and bevacizumab"
        }, 
        "brief_summary": {
            "textblock": "This observational, multicenter, prospective study will evaluate the use of bevacizumab in\n      real clinical practice in chinese patients with metastatic colorectal cancer."
        }, 
        "brief_title": "An Observational Study of Bevacizumab in Chinese Patients With Metastatic Colorectal Cancer", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Metastatic Colorectal Cancer", 
        "condition_browse": {
            "mesh_term": "Colorectal Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  histologically confirmed metastatic colorectal cancer patients Having initiated\n             treatment with bevacizumab\n\n        Exclusion Criteria:\n\n          -  non-metastatic colorectal cancer patients not recieved bevacizumab"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "metastatic colorectal cancer patients accept bevacizumab"
            }
        }, 
        "enrollment": {
            "#text": "250", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 19, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01860144", 
            "org_study_id": "CGOG2001"
        }, 
        "intervention": {
            "arm_group_label": "bevacizumab", 
            "intervention_name": "Bevacizumab", 
            "intervention_type": "Drug", 
            "other_name": "avastin"
        }, 
        "intervention_browse": {
            "mesh_term": "Bevacizumab"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "bevacizumab", 
            "overall survival", 
            "adverse events", 
            "tumor resection rate"
        ], 
        "lastchanged_date": "May 21, 2013", 
        "location": {
            "contact": {
                "email": "lin100@medmail.com.cn", 
                "last_name": "Lin Shen, M.D.", 
                "phone": "861088196561"
            }, 
            "facility": {
                "address": {
                    "city": "Beijing", 
                    "country": "China", 
                    "state": "Beijing", 
                    "zip": "100142"
                }, 
                "name": "Beijing Cancer Hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_groups": "1", 
        "overall_contact": {
            "email": "lin100@medmail.com.cn", 
            "last_name": "Lin Shen, M.D.", 
            "phone": "861088196561"
        }, 
        "overall_contact_backup": {
            "email": "gongjifang@gmail.com", 
            "last_name": "Jifang Gong, M.D.", 
            "phone": "861088196561"
        }, 
        "overall_official": {
            "affiliation": "Beijing Cancer Hopital", 
            "last_name": "Lin Shen, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To evaluate the treatment response of bevacizumab in Chinese patients with mCRC in real clinical practice", 
            "measure": "Objective response rate", 
            "safety_issue": "No", 
            "time_frame": "6 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01860144"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Peking University", 
            "investigator_full_name": "Shen Lin", 
            "investigator_title": "Director of GI oncology", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "OS means that from the first dose of treatment drug to death or lost, the follow-up visit will be performed every 3 months till death or lost", 
                "measure": "overall survival", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "description": "the follow-up visit of PFS will be performed every 6 weeks", 
                "measure": "progression free survival", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }, 
            {
                "description": "Proportion of patients with bevacizumab treatment discontinuation due to bevacizumab-related adverse events", 
                "measure": "Proportion of patients with bevacizumab treatment discontinuation", 
                "safety_issue": "Yes", 
                "time_frame": "3 weeks"
            }, 
            {
                "description": "resection rate of tumor after chemotherapy plus bevacizumab", 
                "measure": "resection rate", 
                "safety_issue": "No", 
                "time_frame": "1 month"
            }
        ], 
        "source": "Peking University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Peking University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2012", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational [Patient Registry]", 
        "target_duration": "2 Years", 
        "verification_date": "May 2013"
    }
}